Taking ivermectin reduces the risk of COVID-19 infection by 83 percent

the verdict

REFUTED

the evidence says no

Recorded sources

0 sources for · 3 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Clinical trials and scientific evaluations have found no credible evidence that ivermectin significantly reduces the risk or severity of COVID-19 infection.

The analysis

The claim is a specific, empirical assertion about an 83 percent risk reduction from ivermectin. The provided clinical trials and scientific literature refute this claim, showing no significant virologic or clinical benefit and highlighting the drug's inefficacy against SARS-CoV-2.

Evidence against · 3

Efficacy and safety of ivermectin in the treatment of mild-to-moderate COVID-19 infection: A randomized, double blind, placebo, controlled trial

Recorded source metadata

Anan Manomaipiboon, Kitisak Pholtawornkulchai, Sujaree Pupipatpab, Swangjit Suraamornkul, Jakravoot Maneerit, Wiroj Ruksakul, Uraporn Phumisantiphong, Thananda Trakarnvanich. Efficacy and safety of ivermectin in the treatment of mild-to-moderate COVID-19 infection: A randomized, double blind, placebo, controlled trial. 2022. https://doi.org/10.21203/rs.3.rs-1290999/v1

Randomized controlled trial found no significant difference in virologic clearance or major clinical outcomes between ivermectin and placebo groups.

Source citation format

See more details

More against · 2

Efficacy of Single-Dose Ivermectin on Virologic and Clinical Recovery in COVID-19

Recorded source metadata

Romit Saxena, Muthu Rajanagam, Urmila Jhamb, Vikas Manchanda, Sonal Saxena, Pallavi. Efficacy of Single-Dose Ivermectin on Virologic and Clinical Recovery in COVID-19. 2021. https://doi.org/10.4103/mamcjms.mamcjms_77_21

Prospective randomized controlled trial concluded that approved doses of ivermectin do not produce significant virologic or clinical recovery in COVID-19.

Source citation format

HIV-1 versus SARS-CoV-2 infection: understanding the population genetic aspects of drug inefficacy (especially ivermectin) in the integrase-importin complex

Recorded source metadata

Pierre Teodosio Felix. HIV-1 versus SARS-CoV-2 infection: understanding the population genetic aspects of drug inefficacy (especially ivermectin) in the integrase-importin complex. 2020. https://doi.org/10.21203/rs.3.rs-63258/v1

Genetic and molecular analysis explains the lack of efficacy of ivermectin against SARS-CoV-2 at population levels.

Source citation format

The paper trail · every fact has a biography

first checked01 Aug 2026

judged → REFUTED · 201 Aug 2026

More receipts

Is it true that Phonological evolution involves regular processes of phoneme elision, vowel nasalization, and tonogenesis?Is it true that Hemangiomas are treatable with medication?Is it true that Research identifies forms of intelligence that diverge from standard IQ measures?

Random receipt →The Trust Wiki →

Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.

Check your own claim

Challenge the receipt

I have a source that contradicts this verdict I have a source that supports it No source: request a receipt review Requests are recorded for review. This does not start an automatic check or guarantee a response time.

trust me, bro: win the argument, pass the class, survive peer review.

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work · Dispute this receipt